)
Visual
test
PMV Pharmaceuticals
PMV Pharmaceuticals (PMVP) investor relations material
PMV Pharmaceuticals Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary6 Mar, 2026
Executive summary
Achieved positive Phase 2 interim data for rezatapopt in the PYNNACLE trial for TP53 Y220C-mutated cancers.
Enrollment remains on track for the pivotal Phase 2 portion, with NDA submission planned for Q1 2027.
Rezatapopt received Orphan Drug Designation and Fast Track status from the FDA for TP53 Y220C positive ovarian cancer.
Published first-in-human data in NEJM showing selective p53 reactivation and antitumor activity.
Financial highlights
Cash, cash equivalents, and marketable securities totaled $112.9 million as of December 31, 2025, down from $183.3 million at year-end 2024.
Net loss for 2025 was $77.7 million, compared to $58.7 million in 2024.
Net cash used in operations was $73.6 million for 2025, up from $51.3 million in 2024.
R&D expenses rose to $69.9 million in 2025, primarily due to advancing rezatapopt clinical development.
G&A expenses decreased to $16.3 million in 2025, reflecting lower facility and personnel costs after relocation and staff reductions.
Outlook and guidance
Cash runway expected to last through the end of Q2 2027.
NDA submission for rezatapopt in platinum-resistant/refractory ovarian cancer planned for Q1 2027.
Detail the latest ovarian cancer ORR data
Assess cash runway beyond Q2 2027
Why is NDA submission limited to ovarian cancer?
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from PMV Pharmaceuticals
- Rezatapopt demonstrates 46% ORR in ovarian cancer, with NDA submission targeted for Q1 2027.PMVP
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - Rezatapopt delivers strong efficacy and safety in TP53 Y220C-mutant cancers, targeting 2027 approval.PMVPCorporate presentation2 Mar 2026
- Interim Phase 2 data for rezatapopt will be released mid-2024, supporting a 2026 NDA filing.PMVPOppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 202517 Dec 2025
- Offering up to $200M in securities to fund oncology R&D, with Jefferies as sales agent.PMVPRegistration Filing16 Dec 2025
- Pivotal Phase II trial of rezatapopt targets 2026 NDA, showing strong efficacy and safety to date.PMVPTD Cowen 45th Annual Healthcare Conference16 Dec 2025
- Director elections, say-on-pay, and auditor ratification headline a governance-focused agenda.PMVPProxy Filing2 Dec 2025
- Virtual annual meeting to vote on directors, executive pay, and auditor ratification.PMVPProxy Filing2 Dec 2025
- Interim phase II data for 50 patients, mainly ovarian, expected July–August; NDA filing options open.PMVPTD Cowen's 6th Annual Oncology Innovation Summit24 Nov 2025
- Phase II basket study for Rezatapopt targets TP53 Y220C, with NDA submission planned for late 2026.PMVPJefferies Global Healthcare Conference 202514 Nov 2025
Next PMV Pharmaceuticals earnings date
Q1 20268 May, 2026
PMV Pharmaceuticals
Next PMV Pharmaceuticals earnings date
Q1 20268 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage